Lexaria Bioscience Corp. financial data

Symbol
LEXX, LEXXW on Nasdaq
Location
100 740 Mccurdy Road, Kelowna, British Columbia, Canada
Fiscal year end
August 31
Latest financial report
10-K - Q3 2025 - Nov 28, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 506 % -70.5%
Quick Ratio 0.96 % -94.4%
Debt-to-equity 21.5 % +215%
Return On Equity -199 % -131%
Return On Assets -162 % -102%
Operating Margin -1.68K % -35.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 22.2M shares +26.6%
Common Stock, Shares, Outstanding 19.6M shares +23.7%
Entity Public Float 24.6M USD -39.4%
Common Stock, Value, Issued 19.6K USD +23.7%
Weighted Average Number of Shares Outstanding, Diluted 18M shares +45.3%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 706K USD +52%
Revenue from Contract with Customer, Excluding Assessed Tax 184K USD +21.6%
Research and Development Expense 8.24M USD +249%
General and Administrative Expense 4.35M USD +12.8%
Operating Income (Loss) -11.9M USD -107%
Nonoperating Income (Expense) -40.2K USD +2.92%
Net Income (Loss) Attributable to Parent -11.9M USD -105%
Earnings Per Share, Diluted 0 USD/shares -40.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.6M USD
Marketable Securities, Current 22.1K USD -60.4%
Accounts Receivable, after Allowance for Credit Loss, Current 368K USD +138%
Inventory, Net 0 USD -100%
Assets, Current 3.47M USD -56.1%
Property, Plant and Equipment, Net 228K USD -10.4%
Operating Lease, Right-of-Use Asset 135K USD -19.5%
Assets 4.18M USD -52.9%
Liabilities, Current 1.49M USD +35.8%
Operating Lease, Liability, Noncurrent 78.9K USD -27.8%
Liabilities 1.57M USD +30.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax -70.3K USD -255%
Retained Earnings (Accumulated Deficit) -63.5M USD -23.1%
Stockholders' Equity Attributable to Parent 2.99M USD -62.8%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 2.6M USD -66%
Liabilities and Equity 4.18M USD -52.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.73M USD -131%
Net Cash Provided by (Used in) Financing Activities 4.35M USD +139%
Net Cash Provided by (Used in) Investing Activities -37.8K USD +5.55%
Common Stock, Shares Authorized 220M shares 0%
Common Stock, Shares, Issued 19.6M shares +23.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 1.58M USD +162%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 1.8M USD -72.3%
Deferred Tax Assets, Valuation Allowance 13.4M USD +25%
Deferred Tax Assets, Gross 13.4M USD +25%
Operating Lease, Liability 109K USD -20.4%
Payments to Acquire Property, Plant, and Equipment 24.6K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -12M USD -106%
Lessee, Operating Lease, Liability, to be Paid 132K USD -21%
Property, Plant and Equipment, Gross 772K USD
Operating Lease, Liability, Current 30.4K USD +8.45%
Lessee, Operating Lease, Liability, to be Paid, Year Two 38.9K USD +4.87%
Lessee, Operating Lease, Liability, to be Paid, Year One 38.6K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, to be Paid, Year Three 8.11K USD -78.3%
Lessee, Operating Lease, Liability, to be Paid, Year Four 8.1K USD -79%
Operating Lease, Payments 8.96K USD -80%
Additional Paid in Capital 66.5M USD +11.6%
Depreciation, Depletion and Amortization 8.73K USD
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 99.4K USD +84.3%